Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

ResMed, a leading manufacturer of CPAP machines for sleep apnea, faces significant long-term disruption from GLP-1 weight loss drugs, which can treat obstructive sleep apnea by addressing obesity, potentially diminishing the need for its devices. Despite this existential threat, the company is paradoxically experiencing short-term benefits as the GLP-1 boom drives increased sleep apnea diagnoses and CPAP prescriptions. This complex dynamic has placed ResMed in an "investment limbo," with analysts closely monitoring the ultimate impact of these breakthrough medical innovations on its core business model.

Analysis

ResMed (RMD), a leading CPAP machine manufacturer, faces a significant long-term threat from GLP-1 weight loss drugs, which address the obesity underlying 70-90% of obstructive sleep apnea cases. Eli Lilly's GLP-1 drug receiving independent approval for sleep apnea treatment without CPAP directly challenges ResMed's core business model.

Paradoxically, ResMed is currently benefiting from the GLP-1 boom, as increased patient engagement for weight loss leads to higher sleep apnea diagnoses and short-term CPAP prescriptions. This creates a complex dynamic of immediate opportunity against an existential long-term risk for the company.

Analysts have placed RMD in an "investment limbo" or "penalty box," maintaining its stock on recommendation lists but with a hold status, reflecting the mixed sentiment and uncertainty. The prevailing strategy involves closely monitoring the material impact of GLP-1 drugs on ResMed's business before making definitive long-term investment decisions.

Key Decisions for Investors

• Monitor the pace and extent of GLP-1 drug adoption and its direct impact on ResMed's CPAP prescription volumes and market share over the next 12-24 months.
• Evaluate ResMed's strategic response to this disruption, including potential diversification into non-obesity related sleep disorders or other healthcare technology innovations.
• Consider the broader implications of breakthrough medical innovations on established device manufacturers, as this case highlights significant industry disruption risks.